Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2008

Nuvelo’s Initiation of Early-Stage Trial Triggers Milestone Payment to Archemix

  • Archemix will receive a $1 million milestone fee from Nuvelo. The payment is a result of Nuvelo’s enrollment of the first volunteer in a Phase I study of NU172, a thrombin-inhibiting aptamer.

    This Phase I trial is being conducted at a single center with approximately 30 males and is designed to determine the safety, tolerability, and pharmacokinetics of escalating doses of the candidate.

    NU172 is an aptamer designed to directly inhibit thrombin’s ability to stimulate blood clot formation, Nuvelo explains. It is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery and percutaneous interventions.

    According to the initial agreement between the firms, Nuvelo is solely responsible for all development and commercialization of NU172. Archemix is eligible to receive additional milestones and will earn royalties. Archemix also retains the option to share in a specified percentage of the profits in exchange for paying an equal percentage of its development and commercialization costs and in lieu of milestone fees and royalties.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »